Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...

Clinical Trials

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

Phase 3

Recruiting

Conditions: Lichen Simplex Chronicus

Interventions: Drug: Dupilumab
Drug: Placebo

First Posted Date: 2024-11-14

Last Posted Date: 2024-12-20

Lead Sponsor: Sanofi

Target Recruit Count: 136

Registration Number: NCT06687967

Locations: 🇨🇦
Investigational Site Number : 1240001, London, Ontario, Canada
🇨🇦
Investigational Site Number : 1240002, Saskatoon, Saskatchewan, Canada
🇯🇵
Investigational Site Number : 3920003, Tachikawa, Tokyo, Japan

and more 1 locations

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Phase 1

Recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Amlitelimab
Drug: Midazolam
Drug: Caffeine
Drug: Metoprolol
Drug: Omeprazole
Drug: Warfarin

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT06686628

Locations: 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

Recruiting

Conditions: Hemophilia A

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2024-11-12

Last Posted Date: 2024-12-02

Lead Sponsor: Sanofi

Target Recruit Count: 120

Registration Number: NCT06684314

Locations: 🇨🇳
Investigational Site Number : 1580008, Changhua, Taiwan
🇨🇳
Investigational Site Number : 1580010, Kaohsiung, Taiwan
🇨🇳
Investigational Site Number : 1580005, Taichung, Taiwan

and more 2 locations

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Lunsekimig
Drug: Short-Acting Beta Agonists (SABA)
Drug: Placebo
Drug: Fluticasone/salmeterol
Drug: Budesonide/formoterol

First Posted Date: 2024-11-06

Last Posted Date: 2024-12-13

Lead Sponsor: Sanofi

Target Recruit Count: 1000

Registration Number: NCT06676319

Locations: 🇺🇸
Clinical Research Associates of Central PA - Dubois- Site Number : 8400013, DuBois, Pennsylvania, United States
🇨🇦
Investigational Site Number : 1240002, Sherbrooke, Quebec, Canada
🇬🇧
Investigational Site Number : 8260005, Barnsley, United Kingdom

and more 5 locations

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Phase 4

Recruiting

Conditions: Type 2 Diabetes (T2D)

Interventions: Drug: iGlarLixi (insulin glargine/lixisenatide)
Drug: Gla-100 (insulin glargine)

First Posted Date: 2024-11-04

Last Posted Date: 2024-12-12

Lead Sponsor: Sanofi

Target Recruit Count: 678

Registration Number: NCT06671587

Locations: 🇨🇳
Investigational Site Number: 1560001, Beijing, China

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Not yet recruiting

Conditions: Chronic Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Adult Immune Thrombocytopenia

First Posted Date: 2024-10-30

Last Posted Date: 2024-12-12

Lead Sponsor: Sanofi

Target Recruit Count: 110

Registration Number: NCT06665308

Locations: 🇬🇧
Imperial College Healthcare NHS Trust,Hammersmith Hospital, Gary Weston Centre_Site Number: 8260001, London, City Of London, United Kingdom

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Phase 1

Not yet recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Biological: SAR402663
Drug: Diluent

First Posted Date: 2024-10-28

Last Posted Date: 2024-10-28

Lead Sponsor: Sanofi

Target Recruit Count: 66

Registration Number: NCT06660667

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Phase 2

Not yet recruiting

Conditions: Crohn's Disease

Interventions: Drug: SAR441566
Drug: SAR441566 matching Placebo

First Posted Date: 2024-10-15

Last Posted Date: 2024-10-15

Lead Sponsor: Sanofi

Target Recruit Count: 260

Registration Number: NCT06637631

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Phase 1

Recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: SAR446523

First Posted Date: 2024-10-08

Last Posted Date: 2024-12-10

Lead Sponsor: Sanofi

Target Recruit Count: 82

Registration Number: NCT06630806

Locations: 🇨🇦
Investigational Site Number : 1240001, Montreal, Quebec, Canada
🇦🇺
Investigational Site Number : 0360001, Wollongong, New South Wales, Australia

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

Phase 4

Recruiting

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Belumosudil

First Posted Date: 2024-09-27

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT06616415

Locations: 🇨🇳
Investigational Site Number: 1560001, Beijing, China
🇨🇳
Investigational Site Number: 1560002, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy